Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8770815 | 0.90 | LCK (0.36) | CARM1PRMT6PRMT8HTR2ALCK | |
| SCHEMBL1068540 | 0.89 | CYP3A4 (0.39) | TAAR1CYP3A4TDP1 | |
| SCHEMBL23637520 | 0.86 | — | — | |
| SCHEMBL23637368 | 0.82 | KIF11 (0.37) | CARM1PRMT6PRMT8TAAR1CYP3A4 | |
| SCHEMBL348351 | 0.80 | KDM4E (0.39) | SMN1; SMN2CYP3A4TDP1 | |
| SCHEMBL18216549 | 0.80 | CYP3A4 (0.32) | CYP3A4TDP1 | |
| SCHEMBL18213635 | 0.80 | HTR1A (0.42) | — | |
| SCHEMBL5039661 | 0.80 | HTR1A (0.42) | — | |
| SCHEMBL8723759 | 0.78 | SIGMAR1 (0.42) | HTR2ASMN1; SMN2CYP3A4HRH1 | |
| SCHEMBL474250 | 0.78 | CYP3A4 (0.41) | LOXL2CYP2A6HTR2ASMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219983-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20230219983-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-07-13 | — | — | US | disclosed |
| US-11639362-B2 | Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| US-11639362-B2 | Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-3848378-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | Takasago International Corporation (JP) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219983-A1 | TETRADENTATE DIAMINODIPHOSPHINE LIGAND AND TRANSITION METAL COMPLEX, AND METHOD FOR MANUFACTURING SAME AND APPLICATION FOR SAME | ADH4, ADH5, PF4 | CARM1 2407/4885PRMT6 846/4885PRMT8 1388/4885 |
| US-11639362-B2 | Tetradentate diaminodiphosphine ligand and transition metal complex, and method for manufacturing same and application for same | ADH4, ADH5, PF4 | CARM1 2407/4885PRMT6 846/4885PRMT8 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.